search
Back to results

The Brain, the Bug, and the Binge: the Interplay Between Binge Drinking, Gut Microbiota, and Brain Functioning

Primary Purpose

Binge Drinking

Status
Recruiting
Phase
Phase 2
Locations
Portugal
Study Type
Interventional
Intervention
Inulin Intervention
Maltodextrin Intervention
Sponsored by
University of Minho
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Binge Drinking focused on measuring Adolescence, Young Adulthood, Alcohol, Binge Drinking, Gut Microbiome, Microbiota-Gut-Brain Axis, Magnetic Resonance Imaging, Pro-inflammatory cytokines, Psychobiotics, Randomized Controlled Trial

Eligibility Criteria

18 Years - 23 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: College students whose native language is Portuguese; Age 18-23 years; Binge Drinkers: report (i) drinking 4 (for women)/5 (for men) or more drinks on one occasion at least once a month, (ii) drinking at a speed of at least two drinks per hour during these episodes (which brings blood alcohol concentration to 0.08 g/dL or above), and (iii) having an AUDIT score < 20. Non/Low-Drinkers: report (i) never drinking 4/5 or more drinks on one occasion and (ii) having an AUDIT score ≤ 4. Exclusion Criteria: Use of illicit drugs as determined by the Drug Use Disorders Identification Test (DUDIT); Alcohol abuse (i.e., AUDIT ≥ 20); Personal history of psychopathological disorders (according to DSM-V criteria); History of traumatic brain injury or neurological disorder; Family history (mother/father) of alcoholism diagnosis of substance abuse; Occurrence of one or more episodes of loss of consciousness for more than 30 minutes; Non-corrected sensory deficits; Diagnosis of any gut disease/problems or other medical conditions: inflammatory bowel disease, irritable bowel syndrome, Crohn's Disease, celiac disease, lactose intolerance, autoimmune disease; Consumption of medical drugs with psychoactive effects (e.g., antidepressants, anxiolytics or benzodiazepines) during the 4 weeks prior to the experiment; Use of any of the following drugs in the last 4 weeks: laxatives, antibiotics, anticoagulants, non-steroidal anti-inflammatory drugs, analgesics, corticosteroids; No type of metal object implanted in the body, especially in the head (orthodontic appliances are not excluded).

Sites / Locations

  • Psychological Neuroscience Laboratory, Psychology Research Center, University of MinhoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Placebo Comparator

No Intervention

Arm Label

Binge Drinkers with Inulin Intervention

Binge Drinkers with Maltodextrin Intervention

Non/Low-Drinkers

Arm Description

23 binge drinkers (~50 % male and ~50 % female) will be given a daily dose of inulin.

23 binge drinkers (~50 % male and ~50 % female) will be given a daily dose of maltodextrin.

36 non/low-drinkers will not be given any dietary fiber.

Outcomes

Primary Outcome Measures

Alcohol Consumption - Drinking pattern
The Alcohol Use Disorder Identification Test (AUDIT) will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Alcohol Consumption - Drinking pattern
The AUDIT will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Alcohol Consumption - Drinking pattern
The AUDIT will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Alcohol Consumption - Drinking pattern
The AUDIT will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Alcohol Craving - Short-term acute craving
Short-term alcohol craving levels will be assessed using the Alcohol Craving Questionnaire - Short form Revised (ACQ-SF-R) at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Alcohol Craving - Short-term acute craving
Short-term alcohol craving levels will be assessed using the Alcohol Craving Questionnaire - Short form Revised (ACQ-SF-R) at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Alcohol Craving - Short-term acute craving
Short-term alcohol craving levels will be assessed using the ACQ-SF-R at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Alcohol Craving - Short-term acute craving
Short-term alcohol craving levels will be assessed using the ACQ-SF-R at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Use of illicit drugs
The use of illicit drugs will be determined by the Drug Use Disorders Identification Test (DUDIT). DUDIT provides information on the level of drug intake and selected criteria for substance abuse/harmful use and dependence according to the ICD-10 and DSM-4 diagnostic systems. In this study, the use of sedative pills, analgesics and tobacco is not an exclusion criterion.
Description of Food Frequency
Habitual dietary intake of each participant will be also measured using a Food Frequency Questionnaire. A detailed description, on average, of nutrients and food group values over the past 12 months will be obtained by classifying the frequency of consumption of each food/beverage type on a scale from never or less than once per month to ≥6 per day.
Food Diary
During the intervention phase, each binge drinker should keep a record of everything they ate and drank during three days of each of the 6 weeks: two days a week and one at the weekend, according to their usual practice. They should also record the type of packaging of the food and drink and the place where they consumed them.
Impulsivity Assessment
The Barratt Impulsiveness Scale (BIS-11) will be used to assess the personality/behavioural construct of impulsiveness including motor (acting without thinking), attentional (an inability to focus attention or concentrate) and non-planning (lack of forethought), in different situations.
Impulsivity Assessment
The Barratt Impulsiveness Scale (BIS-11) will be used to assess the personality/behavioural construct of impulsiveness including motor (acting without thinking), attentional (an inability to focus attention or concentrate) and non-planning (lack of forethought), in different situations.
Neuropsychological Evaluation - Memory
The Delayed Matching to Sample (DMS) from Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess both simultaneous visual matching ability and short-term visual recognition memory, for non-verbalisable patterns.
Neuropsychological Evaluation - Memory
The Delayed Matching to Sample (DMS) from Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess both simultaneous visual matching ability and short-term visual recognition memory, for non-verbalisable patterns.
Neuropsychological Evaluation - Emotion and Social Cognition
The Emotion Recognition Task (ERT) from CANTAB will measure the ability to identify six basic emotions (sadness, happiness, fear, anger, disgust, and surprise) in facial expressions along a continuum of expression magnitude.
Neuropsychological Evaluation - Emotion and Social Cognition
The Emotion Recognition Task (ERT) from CANTAB will measure the ability to identify six basic emotions (sadness, happiness, fear, anger, disgust, and surprise) in facial expressions along a continuum of expression magnitude.
Neuropsychological Evaluation - Executive Function
The performance of the cognitive domain comprising high-level thinking and decision-making will be assessed through CANTAB, namely the Cambridge Gambling Task (CGT, to assess decision-making and risk behaviour outside a learning context), Intra-Extra Dimensional Set Shift (IED, to assess cognitive flexibility), Spatial Working Memory (SWM, to identify working memory strategies and errors) and Stop Signal Task (SST, to measure response inhibition/impulse control).
Neuropsychological Evaluation - Executive Function
The performance of the cognitive domain comprising high-level thinking and decision-making will be assessed through CANTAB, namely the Cambridge Gambling Task (CGT, to assess decision-making and risk behaviour outside a learning context), Intra-Extra Dimensional Set Shift (IED, to assess cognitive flexibility), Spatial Working Memory (SWM, to identify working memory strategies and errors) and Stop Signal Task (SST, to measure response inhibition/impulse control).
Alcohol Cue Reactivity - Emotional measures
The reactivity to alcoholic cues will be assessed using the Alcohol Cue Reactivity (ACR) task. The full task includes a total of 80 trials with 40 alcoholic and 40 non-alcoholic images obtained from the Amsterdam Beverage Picture Set. The emotional responses for each image in terms of valence and arousal task, will be registered using the Self-Assessment Manikin (valence: from 1 = "very unpleasant" to 9 ="very pleasant"; arousal: from 1 = "not arousing" to 9 = "highly arousing") during the ACR task.
Alcohol Cue Reactivity - Emotional measures
The reactivity to alcoholic cues will be assessed using the ACR task. The full task includes a total of 80 trials with 40 alcoholic and 40 non-alcoholic images obtained from the Amsterdam Beverage Picture Set. The emotional responses for each image in terms of valence and arousal task, will be registered using the Self-Assessment Manikin (valence: from 1 = "very unpleasant" to 9 ="very pleasant"; arousal: from 1 = "not arousing" to 9 = "highly arousing") during the ACR task.
Memory Inhibition Performance
Memory Inhibition (MI), specifically alcohol-related MI, will be assessed using the Think/No-Think Alcohol (TNTA) task. Percentage of correct responses (for Think, No-Think and Baseline items) in the TNTA task will be computed according to the following formula: ((number of correctly recalled items)/(number of previously learned items))×100. Correct responses correspond to the items learned during the learning phase and correctly recalled during the memory test phase.
Memory Inhibition Performance
MI, specifically alcohol-related MI, will be assessed using the TNTA task. Percentage of correct responses (for Think, No-Think and Baseline items) in the TNTA task will be computed according to the following formula: ((number of correctly recalled items)/(number of previously learned items))×100. Correct responses correspond to the items learned during the learning phase and correctly recalled during the memory test phase.
Ability of Emotional Recognition
Emotional recognition capacity will be assessed through the Emotion Discrimination (ED) task. ED assesses the brain's preconscious and conscious responses to emotional faces. The complete task includes a total of 120 images of human faces (60 men and 60 women), showing the main negative emotions: angry, sadness and fear.
Ability of Emotional Recognition
Emotional recognition capacity will be assessed through the ED task. ED assesses the brain's preconscious and conscious responses to emotional faces. The complete task includes a total of 120 images of human faces (60 men and 60 women), showing the main negative emotions: angry, sadness and fear.
Fecal Microbiota - Species Richness
Faecal samples will be collected from all participants for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Chao1 Index will be used as an estimator of nonparametric microbial species richness in each sample.
Fecal Microbiota - Species Richness
Faecal samples will be collected only from binge drinkers subjected to the intervention for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Chao1 Index will be used as an estimator of nonparametric microbial species richness in each sample.
Fecal Microbiota - Species Diversity
Faecal samples will be collected from all participants for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Shannon Diversity Index (metric combining richness and evenness, with equal weighting given to abundant and rare species) and the Simpson Diversity Index (metric of richness and evenness, in which more weighting is given to abundant species) will be used.
Fecal Microbiota - Species Diversity
Faecal samples will be collected only from binge drinkers subjected to the intervention for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Shannon Diversity Index (metric combining richness and evenness, with equal weighting given to abundant and rare species) and the Simpson Diversity Index (metric of richness and evenness, in which more weighting is given to abundant species) will be used.
Fecal Microbiota - Quantification of SCFAs levels
The concentration of short-chain fatty acids (SCFAs) present in each collected faecal sample shall be quantified by High Performance Liquid Chromatography (HPLC).
Fecal Microbiota - Quantification of SCFAs levels
The concentration of SCFAs present in each collected faecal sample shall be quantified by HPLC.
Blood samples - Presence of Inflammatory Markers
Blood samples will be collected from all participants. The presence and abundance of the following cytokines will be analyzed: Tumour Necrosis Factor α (TNF-α) and Interleukins (IL-1β, IL-6, IL-10).
Blood samples - Presence of Inflammatory Markers
Blood samples will be collected only from binge drinkers subjected to the intervention. The presence and abundance of the following cytokines will be analyzed: Tumour Necrosis Factor α (TNF-α) and Interleukins (IL-1β, IL-6, IL-10).

Secondary Outcome Measures

Full Information

First Posted
June 15, 2023
Last Updated
July 6, 2023
Sponsor
University of Minho
Collaborators
Foundation for Science and Technology (FCT)
search

1. Study Identification

Unique Protocol Identification Number
NCT05946083
Brief Title
The Brain, the Bug, and the Binge: the Interplay Between Binge Drinking, Gut Microbiota, and Brain Functioning
Official Title
The Brain, the Bug, and the Binge: a Double-blind, Randomized Controlled Trial Investigating the Interplay Between Binge Drinking, Gut Microbiota and Brain Functioning
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 17, 2023 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
August 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Minho
Collaborators
Foundation for Science and Technology (FCT)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Adolescence and youth are periods of significant maturational changes which seems to involve greater susceptibility to disruptive events in the brain such as binge drinking (BD). This prevalent pattern of consumption -characterized by repeated alcohol intoxications- is of special concern, as it has been associated with major neurocognitive impairments in the young brain. Recent studies indicate that alcohol may disrupt the gut microbiota (GM) and that these disruptions may lead to impairments in brain and behavior. Also, interventions with psychobiotics have been shown to result in reductions in alcohol-induced damage and in improvements on cognitive and brain functioning. Thus, the present proposal will explore the effects of BD on GM. Additionally, a GM intervention with psychobiotics both in-vivo and in-vitro, will determine whether improvements in GM composition/function may lead to reductions of alcohol-induced brain damage in BD-population, a barely unexplored research field with major clinical applications.
Detailed Description
The present study protocol aims to determine the interaction between alcohol consumption, brain function and gut microbiota through several levels of analysis, including techniques to measure brain activity (i.e., magnetic resonance imaging), paradigms to measure cognitive performance, collection of stool and blood samples, and questionnaires. Additionally, this study will investigate the relationship between alcohol, brain activity and gut microbiota and how this can be modified through our diet. The sample will be composed by a cohort of young college students (18-23 years) from the University of Minho (UM; Braga, Portugal) selected according to their drinking patterns. Eighty-two participants will be recruited from UM: 36 non/low-drinkers and 46 binge drinkers (BDs) matched for age and gender. Recruitment will be carried out through an online survey broadcasted using the institutional email. This survey will include a simple sociodemographic section and items regarding the use of alcohol (Alcohol Use Disorder Identification Test - AUDIT, frequency of alcohol consumption, number of drinks consumed on each day of the past week, speed of drinking, etc.). After sample selection, participants will be submitted to the following steps: (1) clinical interview - addresses questions relating to psychological, medical, personal and family history, including questions related to history of alcohol and drug use and some specific questionnaires relating to substance use, as well as those related to physical and psychological symptoms, and personality; (2) neuroimaging assessment - will consist of a structural and functional magnetic resonance imaging (fMRI) at the Hospital de Guimarães (Portugal), while performing different cognitive tasks; (3) evaluation of some microorganisms residing in the gut and certain inflammatory markers - each participant will be asked to collect stool and blood samples; (4) evaluation of the potential of an intervention with psychobiotics. Thus, this protocol involves the following phases: pre-intervention, consisting of the assessment of the variables of interest to the study by means of a clinical interview, neuropsychological testing, collection of stool and blood samples, and MRI recordings. intervention (only for BDs), consisting of taking a prebiotic for 6 weeks. Depending on the group to which they will be allocated, the participant will take one of two types of fiber: a fiber with benefits for intestinal bacteria (inulin) or a similar fiber with no specific benefits for the intestinal microbiome (maltodextrin). Each participant will not know which group they belong to in order not to bias the results of the study according to scientific standards. post-intervention, which will consist in the re-assessment of the variables previously assessed in the pre-intervention phase. follow-up, consisting of the assessment and monitoring of levels of alcohol consumption and craving during the 3 months following the intervention phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Binge Drinking
Keywords
Adolescence, Young Adulthood, Alcohol, Binge Drinking, Gut Microbiome, Microbiota-Gut-Brain Axis, Magnetic Resonance Imaging, Pro-inflammatory cytokines, Psychobiotics, Randomized Controlled Trial

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Binge Drinkers will be randomly distributed for one of two groups: 23 subjects with inulin intervention and 23 subjects with maltodextrin intervention (~50 % male and ~50 % female in each group). There will also be a non-interventional control group consisting of 36 non/low-drinkers.
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
82 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Binge Drinkers with Inulin Intervention
Arm Type
Active Comparator
Arm Description
23 binge drinkers (~50 % male and ~50 % female) will be given a daily dose of inulin.
Arm Title
Binge Drinkers with Maltodextrin Intervention
Arm Type
Placebo Comparator
Arm Description
23 binge drinkers (~50 % male and ~50 % female) will be given a daily dose of maltodextrin.
Arm Title
Non/Low-Drinkers
Arm Type
No Intervention
Arm Description
36 non/low-drinkers will not be given any dietary fiber.
Intervention Type
Dietary Supplement
Intervention Name(s)
Inulin Intervention
Intervention Description
For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrin Intervention
Intervention Description
For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
Primary Outcome Measure Information:
Title
Alcohol Consumption - Drinking pattern
Description
The Alcohol Use Disorder Identification Test (AUDIT) will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Time Frame
Screening visit (clinical interview)
Title
Alcohol Consumption - Drinking pattern
Description
The AUDIT will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Time Frame
At baseline (pre-intervention)
Title
Alcohol Consumption - Drinking pattern
Description
The AUDIT will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Time Frame
Immediately post-intervention
Title
Alcohol Consumption - Drinking pattern
Description
The AUDIT will be administered to characterize the drinking pattern of the participants. AUDIT scores ≤ 4 reveal low risk of alcohol use; scores between 5 and 20 represent excessive alcohol consumption; and scores ≥ 20 indicate very high risk for alcohol dependence and warrant further diagnostic evaluation for alcohol dependence.
Time Frame
3 months post-intervention
Title
Alcohol Craving - Short-term acute craving
Description
Short-term alcohol craving levels will be assessed using the Alcohol Craving Questionnaire - Short form Revised (ACQ-SF-R) at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Time Frame
Screening visit (clinical interview)
Title
Alcohol Craving - Short-term acute craving
Description
Short-term alcohol craving levels will be assessed using the Alcohol Craving Questionnaire - Short form Revised (ACQ-SF-R) at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Time Frame
At baseline (pre-intervention)
Title
Alcohol Craving - Short-term acute craving
Description
Short-term alcohol craving levels will be assessed using the ACQ-SF-R at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Time Frame
Immediately post-intervention
Title
Alcohol Craving - Short-term acute craving
Description
Short-term alcohol craving levels will be assessed using the ACQ-SF-R at the present moment. Total minimum score: 1 (low level of alcohol craving); Total maximum score: 7 (high level of alcohol craving).
Time Frame
3 months post-intervention
Title
Use of illicit drugs
Description
The use of illicit drugs will be determined by the Drug Use Disorders Identification Test (DUDIT). DUDIT provides information on the level of drug intake and selected criteria for substance abuse/harmful use and dependence according to the ICD-10 and DSM-4 diagnostic systems. In this study, the use of sedative pills, analgesics and tobacco is not an exclusion criterion.
Time Frame
Screening visit (clinical interview)
Title
Description of Food Frequency
Description
Habitual dietary intake of each participant will be also measured using a Food Frequency Questionnaire. A detailed description, on average, of nutrients and food group values over the past 12 months will be obtained by classifying the frequency of consumption of each food/beverage type on a scale from never or less than once per month to ≥6 per day.
Time Frame
Screening visit (clinical interview)
Title
Food Diary
Description
During the intervention phase, each binge drinker should keep a record of everything they ate and drank during three days of each of the 6 weeks: two days a week and one at the weekend, according to their usual practice. They should also record the type of packaging of the food and drink and the place where they consumed them.
Time Frame
Intervention (6 weeks)
Title
Impulsivity Assessment
Description
The Barratt Impulsiveness Scale (BIS-11) will be used to assess the personality/behavioural construct of impulsiveness including motor (acting without thinking), attentional (an inability to focus attention or concentrate) and non-planning (lack of forethought), in different situations.
Time Frame
Screening visit (clinical interview)
Title
Impulsivity Assessment
Description
The Barratt Impulsiveness Scale (BIS-11) will be used to assess the personality/behavioural construct of impulsiveness including motor (acting without thinking), attentional (an inability to focus attention or concentrate) and non-planning (lack of forethought), in different situations.
Time Frame
3 months post-intervention
Title
Neuropsychological Evaluation - Memory
Description
The Delayed Matching to Sample (DMS) from Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess both simultaneous visual matching ability and short-term visual recognition memory, for non-verbalisable patterns.
Time Frame
At baseline (pre-intervention)
Title
Neuropsychological Evaluation - Memory
Description
The Delayed Matching to Sample (DMS) from Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess both simultaneous visual matching ability and short-term visual recognition memory, for non-verbalisable patterns.
Time Frame
Immediately post-intervention
Title
Neuropsychological Evaluation - Emotion and Social Cognition
Description
The Emotion Recognition Task (ERT) from CANTAB will measure the ability to identify six basic emotions (sadness, happiness, fear, anger, disgust, and surprise) in facial expressions along a continuum of expression magnitude.
Time Frame
At baseline (pre-intervention)
Title
Neuropsychological Evaluation - Emotion and Social Cognition
Description
The Emotion Recognition Task (ERT) from CANTAB will measure the ability to identify six basic emotions (sadness, happiness, fear, anger, disgust, and surprise) in facial expressions along a continuum of expression magnitude.
Time Frame
Immediately post-intervention
Title
Neuropsychological Evaluation - Executive Function
Description
The performance of the cognitive domain comprising high-level thinking and decision-making will be assessed through CANTAB, namely the Cambridge Gambling Task (CGT, to assess decision-making and risk behaviour outside a learning context), Intra-Extra Dimensional Set Shift (IED, to assess cognitive flexibility), Spatial Working Memory (SWM, to identify working memory strategies and errors) and Stop Signal Task (SST, to measure response inhibition/impulse control).
Time Frame
At baseline (pre-intervention)
Title
Neuropsychological Evaluation - Executive Function
Description
The performance of the cognitive domain comprising high-level thinking and decision-making will be assessed through CANTAB, namely the Cambridge Gambling Task (CGT, to assess decision-making and risk behaviour outside a learning context), Intra-Extra Dimensional Set Shift (IED, to assess cognitive flexibility), Spatial Working Memory (SWM, to identify working memory strategies and errors) and Stop Signal Task (SST, to measure response inhibition/impulse control).
Time Frame
Immediately post-intervention
Title
Alcohol Cue Reactivity - Emotional measures
Description
The reactivity to alcoholic cues will be assessed using the Alcohol Cue Reactivity (ACR) task. The full task includes a total of 80 trials with 40 alcoholic and 40 non-alcoholic images obtained from the Amsterdam Beverage Picture Set. The emotional responses for each image in terms of valence and arousal task, will be registered using the Self-Assessment Manikin (valence: from 1 = "very unpleasant" to 9 ="very pleasant"; arousal: from 1 = "not arousing" to 9 = "highly arousing") during the ACR task.
Time Frame
At baseline (pre-intervention)
Title
Alcohol Cue Reactivity - Emotional measures
Description
The reactivity to alcoholic cues will be assessed using the ACR task. The full task includes a total of 80 trials with 40 alcoholic and 40 non-alcoholic images obtained from the Amsterdam Beverage Picture Set. The emotional responses for each image in terms of valence and arousal task, will be registered using the Self-Assessment Manikin (valence: from 1 = "very unpleasant" to 9 ="very pleasant"; arousal: from 1 = "not arousing" to 9 = "highly arousing") during the ACR task.
Time Frame
Immediately post-intervention.
Title
Memory Inhibition Performance
Description
Memory Inhibition (MI), specifically alcohol-related MI, will be assessed using the Think/No-Think Alcohol (TNTA) task. Percentage of correct responses (for Think, No-Think and Baseline items) in the TNTA task will be computed according to the following formula: ((number of correctly recalled items)/(number of previously learned items))×100. Correct responses correspond to the items learned during the learning phase and correctly recalled during the memory test phase.
Time Frame
At baseline (pre-intervention)
Title
Memory Inhibition Performance
Description
MI, specifically alcohol-related MI, will be assessed using the TNTA task. Percentage of correct responses (for Think, No-Think and Baseline items) in the TNTA task will be computed according to the following formula: ((number of correctly recalled items)/(number of previously learned items))×100. Correct responses correspond to the items learned during the learning phase and correctly recalled during the memory test phase.
Time Frame
Immediately post-intervention.
Title
Ability of Emotional Recognition
Description
Emotional recognition capacity will be assessed through the Emotion Discrimination (ED) task. ED assesses the brain's preconscious and conscious responses to emotional faces. The complete task includes a total of 120 images of human faces (60 men and 60 women), showing the main negative emotions: angry, sadness and fear.
Time Frame
At baseline (pre-intervention)
Title
Ability of Emotional Recognition
Description
Emotional recognition capacity will be assessed through the ED task. ED assesses the brain's preconscious and conscious responses to emotional faces. The complete task includes a total of 120 images of human faces (60 men and 60 women), showing the main negative emotions: angry, sadness and fear.
Time Frame
Immediately post-intervention.
Title
Fecal Microbiota - Species Richness
Description
Faecal samples will be collected from all participants for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Chao1 Index will be used as an estimator of nonparametric microbial species richness in each sample.
Time Frame
At baseline (pre-intervention)
Title
Fecal Microbiota - Species Richness
Description
Faecal samples will be collected only from binge drinkers subjected to the intervention for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Chao1 Index will be used as an estimator of nonparametric microbial species richness in each sample.
Time Frame
Immediately post-intervention.
Title
Fecal Microbiota - Species Diversity
Description
Faecal samples will be collected from all participants for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Shannon Diversity Index (metric combining richness and evenness, with equal weighting given to abundant and rare species) and the Simpson Diversity Index (metric of richness and evenness, in which more weighting is given to abundant species) will be used.
Time Frame
At baseline (pre-intervention)
Title
Fecal Microbiota - Species Diversity
Description
Faecal samples will be collected only from binge drinkers subjected to the intervention for microbiota α-diversity analysis by 16S rRNA metagenomics (Illumina sequencing). The Shannon Diversity Index (metric combining richness and evenness, with equal weighting given to abundant and rare species) and the Simpson Diversity Index (metric of richness and evenness, in which more weighting is given to abundant species) will be used.
Time Frame
Immediately post-intervention.
Title
Fecal Microbiota - Quantification of SCFAs levels
Description
The concentration of short-chain fatty acids (SCFAs) present in each collected faecal sample shall be quantified by High Performance Liquid Chromatography (HPLC).
Time Frame
At baseline (pre-intervention)
Title
Fecal Microbiota - Quantification of SCFAs levels
Description
The concentration of SCFAs present in each collected faecal sample shall be quantified by HPLC.
Time Frame
Immediately post-intervention.
Title
Blood samples - Presence of Inflammatory Markers
Description
Blood samples will be collected from all participants. The presence and abundance of the following cytokines will be analyzed: Tumour Necrosis Factor α (TNF-α) and Interleukins (IL-1β, IL-6, IL-10).
Time Frame
At baseline (pre-intervention)
Title
Blood samples - Presence of Inflammatory Markers
Description
Blood samples will be collected only from binge drinkers subjected to the intervention. The presence and abundance of the following cytokines will be analyzed: Tumour Necrosis Factor α (TNF-α) and Interleukins (IL-1β, IL-6, IL-10).
Time Frame
Immediately post-intervention.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
23 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: College students whose native language is Portuguese; Age 18-23 years; Binge Drinkers: report (i) drinking 4 (for women)/5 (for men) or more drinks on one occasion at least once a month, (ii) drinking at a speed of at least two drinks per hour during these episodes (which brings blood alcohol concentration to 0.08 g/dL or above), and (iii) having an AUDIT score < 20. Non/Low-Drinkers: report (i) never drinking 4/5 or more drinks on one occasion and (ii) having an AUDIT score ≤ 4. Exclusion Criteria: Use of illicit drugs as determined by the Drug Use Disorders Identification Test (DUDIT); Alcohol abuse (i.e., AUDIT ≥ 20); Personal history of psychopathological disorders (according to DSM-V criteria); History of traumatic brain injury or neurological disorder; Family history (mother/father) of alcoholism diagnosis of substance abuse; Occurrence of one or more episodes of loss of consciousness for more than 30 minutes; Non-corrected sensory deficits; Diagnosis of any gut disease/problems or other medical conditions: inflammatory bowel disease, irritable bowel syndrome, Crohn's Disease, celiac disease, lactose intolerance, autoimmune disease; Consumption of medical drugs with psychoactive effects (e.g., antidepressants, anxiolytics or benzodiazepines) during the 4 weeks prior to the experiment; Use of any of the following drugs in the last 4 weeks: laxatives, antibiotics, anticoagulants, non-steroidal anti-inflammatory drugs, analgesics, corticosteroids; No type of metal object implanted in the body, especially in the head (orthodontic appliances are not excluded).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eduardo G. López-Caneda, PhD
Phone
(+351) 253 604 223
Email
eduardo.lopez@psi.uminho.pt
First Name & Middle Initial & Last Name or Official Title & Degree
Clarisse N. Gonçalves, PhD
Email
clarissenobre@deb.uminho.pt
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eduardo G. López-Caneda, PhD
Organizational Affiliation
Psychological Neuroscience Laboratory, Psychology Research Center, University of Minho, Portugal.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Psychological Neuroscience Laboratory, Psychology Research Center, University of Minho
City
Braga
State/Province
Gualtar, Braga
ZIP/Postal Code
4710-057
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eduardo G. López-Caneda, PhD
Phone
(+351) 253 604 223
Email
eduardo.lopez@psi.uminho.pt
First Name & Middle Initial & Last Name & Degree
Clarisse N. Gonçalves, PhD
Email
clarissenobre@deb.uminho.pt
First Name & Middle Initial & Last Name & Degree
Sónia S. Sousa, PhD
First Name & Middle Initial & Last Name & Degree
Carina Carbia, PhD
First Name & Middle Initial & Last Name & Degree
Natália A. Almeida-Antunes, PhD Student
First Name & Middle Initial & Last Name & Degree
Rui S. Rodrigues, PhD Student
First Name & Middle Initial & Last Name & Degree
Pedro S. Azevedo, PhD Student
First Name & Middle Initial & Last Name & Degree
Diogo P. Martins, MS

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36739238
Citation
Carbia C, Bastiaanssen TFS, Iannone LF, Garcia-Cabrerizo R, Boscaini S, Berding K, Strain CR, Clarke G, Stanton C, Dinan TG, Cryan JF. The Microbiome-Gut-Brain axis regulates social cognition & craving in young binge drinkers. EBioMedicine. 2023 Mar;89:104442. doi: 10.1016/j.ebiom.2023.104442. Epub 2023 Feb 2.
Results Reference
background
PubMed Identifier
31487578
Citation
Sousa SS, Sampaio A, Marques P, Lopez-Caneda E, Goncalves OF, Crego A. Functional and structural connectivity of the executive control network in college binge drinkers. Addict Behav. 2019 Dec;99:106009. doi: 10.1016/j.addbeh.2019.05.033. Epub 2019 Jun 3.
Results Reference
background
PubMed Identifier
33418172
Citation
Almeida-Antunes N, Crego A, Carbia C, Sousa SS, Rodrigues R, Sampaio A, Lopez-Caneda E. Electroencephalographic signatures of the binge drinking pattern during adolescence and young adulthood: A PRISMA-driven systematic review. Neuroimage Clin. 2021;29:102537. doi: 10.1016/j.nicl.2020.102537. Epub 2020 Dec 17.
Results Reference
background
PubMed Identifier
24881329
Citation
White A, Hingson R. The burden of alcohol use: excessive alcohol consumption and related consequences among college students. Alcohol Res. 2013;35(2):201-18.
Results Reference
background
PubMed Identifier
33288871
Citation
Carbia C, Lannoy S, Maurage P, Lopez-Caneda E, O'Riordan KJ, Dinan TG, Cryan JF. A biological framework for emotional dysregulation in alcohol misuse: from gut to brain. Mol Psychiatry. 2021 Apr;26(4):1098-1118. doi: 10.1038/s41380-020-00970-6. Epub 2020 Dec 7.
Results Reference
background
PubMed Identifier
22968153
Citation
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012 Oct;13(10):701-12. doi: 10.1038/nrn3346. Epub 2012 Sep 12.
Results Reference
background
PubMed Identifier
31753762
Citation
Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020 Feb;19(2):179-194. doi: 10.1016/S1474-4422(19)30356-4. Epub 2019 Nov 18.
Results Reference
background
PubMed Identifier
25288760
Citation
Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Starkel P, Windey K, Tremaroli V, Backhed F, Verbeke K, de Timary P, Delzenne NM. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4485-93. doi: 10.1073/pnas.1415174111. Epub 2014 Oct 6.
Results Reference
background
PubMed Identifier
28244981
Citation
Leclercq S, de Timary P, Delzenne NM, Starkel P. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Transl Psychiatry. 2017 Feb 28;7(2):e1048. doi: 10.1038/tp.2017.15.
Results Reference
background
PubMed Identifier
30172845
Citation
Jadhav KS, Peterson VL, Halfon O, Ahern G, Fouhy F, Stanton C, Dinan TG, Cryan JF, Boutrel B. Gut microbiome correlates with altered striatal dopamine receptor expression in a model of compulsive alcohol seeking. Neuropharmacology. 2018 Oct;141:249-259. doi: 10.1016/j.neuropharm.2018.08.026. Epub 2018 Aug 31.
Results Reference
background
PubMed Identifier
30031625
Citation
Leclercq S, Starkel P, Delzenne NM, de Timary P. The gut microbiota: A new target in the management of alcohol dependence? Alcohol. 2019 Feb;74:105-111. doi: 10.1016/j.alcohol.2018.03.005. Epub 2018 Mar 20.
Results Reference
background
PubMed Identifier
31328014
Citation
Lannoy S, Billieux J, Dormal V, Maurage P. Behavioral and Cerebral Impairments Associated with Binge Drinking in Youth: A Critical Review. Psychol Belg. 2019 Mar 29;59(1):116-155. doi: 10.5334/pb.476.
Results Reference
background
PubMed Identifier
30375668
Citation
Lopez-Caneda E, Crego A, Campos AD, Gonzalez-Villar A, Sampaio A. The Think/No-Think Alcohol Task: A New Paradigm for Assessing Memory Suppression in Alcohol-Related Contexts. Alcohol Clin Exp Res. 2019 Jan;43(1):36-47. doi: 10.1111/acer.13916. Epub 2018 Nov 25.
Results Reference
background

Learn more about this trial

The Brain, the Bug, and the Binge: the Interplay Between Binge Drinking, Gut Microbiota, and Brain Functioning

We'll reach out to this number within 24 hrs